[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoarthritis-hip\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoarthritis-hip":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,43,72,102,128,158,190,214,240,281,312,343,373,414,440,463,492,527,550,577,603,630,656,683,703],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100639836","intravenous-dexamethasone-0-vs-4-vs-8-mg-as-an-adjunct-to-peng-block-for-postoperative-analgesia-in-total-hip-arthroplasty-a-randomized-double-blind-trial-100639836",false,"NCT07581470","Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty: A Randomized Double-Blind Trial","A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Scheduled for elective total hip arthroplasty (THA)\n* Planned use of regional anesthesia including PENG block\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Ability to understand the study procedures and provide written informed consent\n* Ability to assess pain using the Numeric Rating Scale (NRS)\n\nExclusion Criteria:\n\n* Known hypersensitivity to dexamethasone or any component of the study medication\n* Chronic corticosteroid therapy or use of systemic steroids within 14 days prior to surgery\n* Active systemic infection or sepsis\n* Significant immunosuppression (e.g., chemotherapy, biological therapy)\n* Pregnancy or breastfeeding\n* Severe cognitive impairment or inability to reliably assess pain\n* Uncontrolled diabetes mellitus (e.g., HbA1c \\> 8.5% or baseline blood glucose \\> 200 mg\u002FdL)","ALL","18 Years","100 Years",{"count":21,"type":22},198,"ESTIMATED","INTERVENTIONAL",[25],"NA","his study will test whether giving dexamethasone through a vein can improve pain control after total hip replacement surgery. Dexamethasone is commonly used to reduce nausea and may also help with pain, but it is not clear which dose works best. Patients will be randomly assigned to receive either no dexamethasone, 4 mg, or 8 mg, in addition to standard anesthesia and a nerve block (PENG block). The main goal is to see how long patients go without needing additional pain medication after surgery. The study will also look at pain levels, use of opioid painkillers, nausea and vomiting, blood sugar levels, and possible side effects.",[28,29],"Osteoarthritis, Hip","Hip Osteoarthritis","RECRUITING","2026-06-29",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":34},"2026-05-08",{"date":38,"type":22},"2027-07-31",{"name":40,"class":41},"Poznan University of Medical Sciences","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100583599","cannabinoids-for-osteoarthritis-pain-effectiveness-trial-100583599","NCT06878417","Cannabinoids for Osteoarthritis Pain Effectiveness Trial","The Effectiveness of Oral Cannabis Extracts for Osteoarthritic Pain: an Internal Pilot, Placebo Controlled, Blinded Randomized Trial","COPE","Inclusion Criteria:\n\n1. Age 40-80 years\n2. Diagnosed with hip and\u002For knee osteoarthritis as per the American College of Rheumatology criteria\n3. Experiencing moderate to severe pain interference as indicated by a PROMIS-PI SF-6a T-score ≥ 60\n4. Have not initiated any new analgesics or osteoarthritis treatments in the previous 4 weeks\n5. Able to self-report, understand and read English or French\n\nExclusion Criteria:\n\n1. Hip or knee surgery planned in the coming 4 months,\n2. Injection into the affected joint(s) within the past 3 months (e.g., cortisone, plasma-rich protein, etc.),\n3. Planned injection into the affected joint(s) during trial period,\n4. Inflammatory arthritis (e.g., rheumatoid arthritis, Psoriatic arthritis, gout, etc.),\n5. Contraindications to taking cannabis\u002Fcannabinoids,\n6. Used nabilone or nabiximols in the last 30 days,\n7. Used cannabis (medical or recreational) in the last 30 days (to allow sufficient washout),\n8. A history of diagnosed cannabis use disorder or dependence,\n9. Active substance use disorder,\n10. Current DSM-V diagnosis of bipolar disorder, major depression, or psychosis,\n11. An uncontrolled medical or major psychiatric disorder,\n12. Currently on warfarin,\n13. Known pregnancy or currently breastfeeding,\n14. Men and women planning a pregnancy during the study or in the 12 weeks after stopping IPs\n15. No fixed address or a plan to change addresses in the coming 4 months,\n16. Known or suspected allergy to palm\u002Fcoconut oil","40 Years","80 Years",{"count":54,"type":22},100,[25],"This study aims to investigate whether oral cannabis extracts can effectively manage pain caused by osteoarthritis (OA), a common joint condition affecting one in seven Canadians. Current OA treatments often have limited effectiveness and may cause side effects. As a result, many individuals with OA turn to medical cannabis for pain relief, despite limited scientific evidence supporting its efficacy.\n\nThe goal of this study is to assess the feasibility of a larger trial evaluating the effects of two cannabis compounds-CBD and THC-compared to a placebo (a look-alike substance containing no active drug) on pain interference in patients with hip and\u002For knee osteoarthritis.\n\nParticipants will:\n\n* Take either CBD, THC, or a placebo capsule daily for 8 weeks\n* Complete follow-ups remotely, with no in-person clinic visits required\n* Maintain a diary tracking their study drug usage and any additional pain medications",[58,59],"Osteoarthritis of Knee","Osteoarthritis Hip",[61],"Medical Cannabis","2026-06-17",{"date":64,"type":34},"2026-06-22",{"date":66,"type":34},"2026-01-29",{"date":68,"type":22},"2027-02-28",{"name":70,"class":41},"University Health Network, Toronto",3,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":42},"100596639","prehabilitation-in-older-people-undergoing-total-hip-replacement-100596639","NCT07048080","Prehabilitation in Older People Undergoing Total Hip Replacement","(P)Rehabilitation in Older People With Osteoarthritis Undergoing Total Hip Replacement : From Physicological Mechanism to Clinical Benefits","PREHIP","Inclusion Criteria:\n\n* Individuals aged from 60 y and over.\n* 18.5 \\\u003C BMI \\\u003C 40 kg\u002Fm2.\n* Individuals on waiting list to undergo a unilateral elective surgery for Total Hip Replacement due to primary severe Osteoarthritis.\n\nExclusion Criteria:\n\n* Individuals with severe OA in the contralateral hip.\n* Individuals who has been performing regular RET (2 or more times per week) in the previous 6 months.\n* Individuals who smoke.\n* Significant psychiatric or neurological disorders, with the use of acetylcholinesterase inhibitors, and untreated mood disorders or depressive pathology.\n* Neuromuscular or mobility disorders that prevent safe resistance training (debilitating arthritis, spasticity\u002Frigidity, and paralysis), along with untreated metabolic disorders (such as uncontrolled systemic hypertension).","60 Years",{"count":82,"type":22},70,[25],"The goal of this clinical trial is to determine the effect of Resistance Exercise Training (RET)-based (p)rehabilitation versus usual care on skeletal muscle mass and function, as well as on underlying biological processes, in older adults undergoing elective Total Hip Replacement (THR) due to severe Osteoarthritis (OA). The main questions it aims to answer are:\n\n* What is the effects of RET-based (p)rehabilitation versus usual care to improve muscle mass and function in patients undergoing elective unilateral THR surgery for end-stage OA?\n* What is the potential of certain circulating biomarkers to predict the efficacy of the musculoskeletal system response to RET in patients with severe OA? Researchers will compare RET-based (p)rehabilitation versus usual care to see if RET works to increase skeletal muscle mass and function.\n\nParticipants in the usual care group will undergo standard rehabilitation (12 weeks post-surgery), and participants in the (p)rehabilitation group will undergo RET-based full-body (p)rehabilitation (3x\u002Fweek) for 2 weeks pre-surgery and 12 weeks post-surgery.",[86,28],"Hip Replacement in Osteoarthritis Patients",[88,89,90,91],"hip osteoarthritis","total hip replacement","resistance exercise training","older people","NOT_YET_RECRUITING","2026-06-10",{"date":95,"type":34},"2026-06-12",{"date":97,"type":22},"2026-08-02",{"date":99,"type":22},"2029-03",{"name":101,"class":41},"Universidad de La Frontera",{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":42},"100418585","study-of-parameters-of-osteosarcopenia-in-patients-with-hip-fracture-100418585","NCT04730622","Study of Parameters of Osteosarcopenia in Patients With Hip Fracture","Study of Parameters of Bone Fragility and Sarcopenia in Patients Undergoing Surgery for Fracture of the Femoral Neck","Inclusion Criteria:\n\n* Patients who came to observation with femoral neck fracture of possible osteoporotic nature (no or minimal trauma) to be treated with endoprosthesis or hip arthroplasty.\n* Competent patients who have signed consent to participate in the study (see Informed Consent section of this protocol).\n\nExclusion Criteria:\n\n* Previous osteoporotic fractures\n* Previous prosthetic surgery for orthopedic diseases\n* Pre-existing clinical conditions that led to permanent immobility\n* Neoplastic diseases\n* Autoimmune diseases\n* Severe myopathies\n* Chronic viral infections (HBV, HCV, HIV);\n* Chronic treatment with anti-osteoporotic drugs, immunosuppressive drugs, and insulin\n* Paget's disease","65 Years",{"count":54,"type":22},"OBSERVATIONAL","The study aims to assess the adequacy of a set of clinical and laboratory investigations for identifying the osteosarcopenia status in patients undergoing a hip replacement for a fragility fracture of the femoral neck. The control group will consist of patients undergoing a hip replacement for osteoarthritis, as the decrease in muscle function and bone quality is less severe in this condition than in osteoporosis.",[114,28],"Osteoporotic Fracture of Femur",[116,117,118],"Osteoporosis","Sarcopenia","Hip prosthesis","2026-05-20",{"date":121,"type":34},"2026-05-22",{"date":123,"type":34},"2020-11-23",{"date":125,"type":22},"2026-12-31",{"name":127,"class":41},"Istituto Ortopedico Rizzoli",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":157},"100466718","safety-and-effectiveness-of-the-hit-reverse-hrs-100466718","NCT05357378","Safety and Effectiveness of the HIT Reverse HRS","Safety and Effectiveness of the Hip Innovation Technology Reverse Hip Replacement System in Primary Total Hip Arthroplasty: A Pivotal Study","Inclusion Criteria:\n\n* Patient requires primary THA due to NIDJD or any of its composite diagnoses such as osteoarthritis, avascular necrosis, posttraumatic arthritis, slipped capital epiphysis, fracture of the pelvis, and diastrophic variant requiring unilateral primary THA.\n* Patient is between 50 (inclusive) and 75 (inclusive) years of age at the time of enrollment.\n* Patient has preoperative medical clearance and is free from or treated for medical conditions that would pose excessive operative risk.\n* Patient has a signed and dated Informed Consent Form (ICF).\n* Patient is willing and able to participate in required follow-up visits at the investigational site and to complete study procedures and questionnaires.\n\nExclusion Criteria:\n\n* Patient has received earlier THA, hemi-arthroplasty, or fusion in the contralateral hip in the last 24 months.\n* Patient has received earlier THA, hemi-arthroplasty, or fusion in the contralateral hip more than 24 months ago and has a contralateral hip-specific pain rating of ≥2 on a Numeric Rating Scale 0-10.\n* Patient needs bilateral hip replacement or has a planned THA on the contralateral hip joint in the next 24 months.\n* Patient needs knee arthroplasty or has a planned total knee arthroplasty in the next 24 months.\n* Patient has a known allergy to titanium and\u002For XLPE.\n* Patient has known metal sensitivities to cobalt chromium (CoCr).\n* Patient has a history of septic arthritis in the index joint.\n* Patient has insufficient acetabular or femoral bone stock in which good anchorage of the implants is unlikely or impossible.\n* Patient has total or partial absence of the muscular or ligamentous apparatus.\n* Patient has known moderate to severe renal insufficiency.\n* Patient has vascular insufficiency, muscular atrophy, or neuromuscular disease in either leg (based on the Investigator's judgment).\n* Patient has a deformity of the affected limb or significant anatomic variance of the affected hip.\n* Patient has an active malignancy or history of invasive malignancy within the last 5 years, except for superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix definitively treated more than 1 year prior to enrollment may enter the study.\n* Patient has Paget's disease, Charcot-Marie-Tooth disease, or osteomalacia.\n* Patient has an inflammatory DJD including any of its composite diagnoses: rheumatoid arthritis, systemic lupus erythematosus, pigmented villonodular synovitis, juvenile rheumatoid arthritis, and other arthritic processes of inflammatory or autoimmune etiology.\n* Patient has any condition that would interfere with self-assessment of pain, function, or quality of life (QoL) required for patient-reported outcomes during the study (based on the Investigator's judgment).\n* Patient has a Body Mass Index (BMI) of 40 or higher.\n* Patient has an active infection (e.g., hepatitis, Acquired Immune Deficiency Syndrome (AIDS), AIDS-related Complex (ARC)) that is systemic or at the site of the intended surgery.\n* Patient is currently participating in any investigational study not related to this study's preoperative or postoperative care.\n* Patient is currently pregnant or is planning to become pregnant during the study.\n* Patient is a competitive or professional athlete.","50 Years","75 Years",{"count":138,"type":22},288,[25],"The purpose of this study is to determine if the use of the HIT Reverse Hip Replacement System is safe and effective in patients undergoing total hip replacement. We will determine whether it is safe and effective by comparing it to the control devices.",[142,28,143,144],"Degenerative Joint Disease","Avascular Necrosis of Hip","Traumatic Arthropathy-Hip",[146],"total hip arthroplasty","2026-05-07",{"date":149,"type":34},"2026-05-11",{"date":151,"type":34},"2022-07-15",{"date":153,"type":22},"2035-07-15",{"name":155,"class":156},"Hip Innovation Technology","INDUSTRY",6,{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":175,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":42},"100527265","promoting-sleep-to-alleviate-pain---arthroplasty-100527265","NCT06145516","Promoting Sleep to Alleviate Pain - Arthroplasty","Preoperative Sleep-promotion to Achieve Improved Postoperative Pain Control and Recovery: a Randomized, Controlled Trial","PROSAP-A","Inclusion Criteria:\n\n* age ≥18 years\n* insomnia severity index score \\>10\n* fulfill DSM-V criteria for persistent insomnia disorder\n* average pain numerical rating scale (NRS) score ≥4 (scale 0 - 10) and\u002For movement-related pain NRS score ≥4 after 5 minutes walking\n* scheduled to undergo primary (first-time, i.e., not revision surgery) TKA or THA due to osteoarthritis\n\nExclusion Criteria:\n\n* uncontrolled medical disorders\n* nightshift work\n* ongoing major depressive disorder, bipolar disorder, psychotic disorder, substance dependence\n* current history or high likelihood of primary sleep disorders (other than insomnia), including obstructive sleep apnea syndrome, narcolepsy, nocturnal myoclonus\n* severely impaired vision (precluding ability to take part of study interventions)",{"count":54,"type":22},[25],"PROSAP-A is a perioperative randomized, controlled trial with a 12-month follow-up period after total knee arthroplasty (TKA) or total hip arthroplasty (THA), aiming to investigate both acute and long-term postoperative effects of preoperative sleep-promotion. Participants with clinically significant insomnia symptoms will be randomized to a brief, hybrid version of cognitive behavioral therapy for insomnia (CBT-I) or sleep education therapy, administered over a 4-week period, prior to surgery. The primary objective is to evaluate effects of preoperative sleep-promotion on acute postoperative pain control. Secondary objectives include evaluation of postoperative sleep, recovery, mental health, cognitive function and alterations in blood biomarkers.",[170,28,171,172,173,174],"Osteoarthritis, Knee","Insomnia","Surgery","Pain, Postoperative","Postoperative Complications",[176,177,146,178,179,180],"osteoarthritis","total knee arthroplasty","insomnia","sleep disturbance","postoperative pain","2026-04-29",{"date":183,"type":34},"2026-05-06",{"date":185,"type":34},"2025-09-01",{"date":187,"type":22},"2030-12-01",{"name":189,"class":41},"Uppsala University",{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":197,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":42},"100458222","metabolic-profiling-of-hematopoietic-stem-cells-in-clonal-hematopoiesis-chip-100458222","NCT05246813","Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)","Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP): a Prospective Observational Study","Inclusion Criteria:\n\n* Age 65 years and older\n\nExclusion Criteria:\n\n* known haematological condition (myelodysplasia, leukemia, cancer)\n* inability to provide written informed consent","55 Years",{"count":199,"type":22},24,"Bone marrow samples will be collected from patients undergoing hip arthroplasty surgery. Blood and bone marrow samples will be used for metabolic profiling and analysis of relevant CHIP mutations. Combined single-cell transcriptomics and mutation-specific single-cell genotyping (biotin-PCR using mutation-targeted primers followed by sequencing) will subsequently be performed. The gene expression profile of wildtype and mutant hematopoietic stem cells will be compared, performing both broad gene set enrichment analysis and targeted analysis of metabolic pathways.",[116,28,202,203,204],"Hip Fractures","Clonal Hematopoiesis of Indeterminate Potential","Aging","2026-03-24",{"date":207,"type":34},"2026-03-25",{"date":209,"type":34},"2022-02-11",{"date":211,"type":22},"2030-12-31",{"name":213,"class":41},"Imelda Hospital, Bonheiden",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":239},"100491987","observational-study-to-evaluate-long-term-outcome-in-hip-hemiarthroplasty-100491987","NCT05686278","Observational Study to Evaluate Long-Term Outcome in Hip Hemiarthroplasty","A Post-market Clinical Follow-up (PMCF) Study to Evaluate Clinical, Radiographic and Patient Reported Outcomes Following a Hip Hemiarthroplasty Surgery Using Corin Devices","Inclusion Criteria:\n\n1. Both genders.\n2. Adult subjects.\n3. Subjects clinically suitable for a hip hemiarthroplasty surgery with Corin hip devices based on physical examination, medical history and diagnosis such as: non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis in which the acetabulum does not require replacement, treatment of non-union, femoral neck and trochanteric fractures of the proximal femur, revision of failed partial hip replacements in which the acetabulum does not require replacement.\n4. The subject is willing to comply with the required follow-up visits as per protocol.\n5. The subject, or a designated trusted person in case the subject is unable to do, has signed a Patient Informed Consent Form (PICF), specific to this study, and approved by the local EC.\n\nExclusion Criteria:\n\n1. Subjects with active infection or sepsis or osteomyelitis.\n2. Subjects with unsuitable or insufficient bone support preventing proper fixation of the prosthesis.\n3. Subject with marked bone loss or bone absorption.\n4. Subject with metabolic disorders which may impair bone formation or bone quality.\n5. Subjects under guardianship.\n6. Subjects under jusicial protection\n7. Subjects in the opinion of the Investigator\u002F investigative team who will be unable to comply with study procedures (Examples: recent psychotic or mania disorders, alcohol, drug or substance abusers) and\u002For those unable for any medical or other reason to comply with study procedures\u002Fvisits.",{"count":222,"type":22},368,"This PMCF study is designed to collect safety and efficacy data on hip hemiarthroplasty surgeries with Corin BiPolar-i shell and the Oceane+ or Meije Duo femoral stem up to 10 years.",[202,225,28,143,226],"Hip Hemiarthroplasty","Femoral Neck Fractures",[228,229,202],"Hemiarthroplasty","Acetabulum","2026-03-17",{"date":232,"type":34},"2026-03-18",{"date":234,"type":34},"2023-06-29",{"date":236,"type":22},"2035-09",{"name":238,"class":156},"Corin",4,{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":262,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":42},"100598260","feasibility-of-choose-to-move-replacement-ready-100598260","NCT07069179","Feasibility of Choose to Move Replacement Ready","Choose to Move Replacement Ready: A Feasibility Trial of a Virtual Health-promoting Intervention for People Awaiting Total Hip or Knee Replacement Surgery","CTM-RR","Inclusion Criteria:\n\n1. Activity coach hired by the Active Aging Society (activity coaches must speak English to participate in the evaluation);\n2. English-speaking older adults (aged \\>=50 years) who participate in CTM-RR will be invited to participate in the evaluation\n3. Referral partner (People who work in a healthcare setting who refer patients into the program)\n\nExclusion Criteria:\n\n1. non-English speaking activity coach\n2. non-English speaking referral partner",{"count":249,"type":22},60,[25],"Choose to Move (CTM) is a 3-month, choice-based health-promoting program for low active older adults being scaled-up across British Columbia (BC), Canada. Recently, the investigators adapted CTM for the \\>14000 people in BC who are on surgical waitlists for total knee replacement or total hip replacement (TKR\u002FTHR) for osteoarthritis (OA). The primary goal of this observational study is to learn if the adapted program, Choose to Move Replacement Ready (CTM-RR), is feasible to deliver to people with hip and\u002For knee osteoarthritis who are on surgical waitlists for TKR\u002FTHR.\n\nParticipants who enrol in CTM-RR will answer online survey questions about the program and about their physical activity, mobility, pain, function, quality of life, willingness to undergo surgery, overall perception of their joint condition, psychosocial health, self-efficacy, social isolation, loneliness, and sedentary time. CTM-RR activity coaches will also answer online survey questions about the program. CTM-RR participants, activity coaches, and referral partners will also participate in interviews about the program.",[253,254,28,255,256,257,258,259,260,261],"Osteoarthritis","Osteoarthritis (OA) of the Knee","Total Knee Arthroplasty; Total Hip Arthroplasty","Mobility Limitation","Social Isolation or Loneliness","Pain","Implementation Science","Physical Inactivity","Sedentary Behaviors",[253,263,264,265,266,267,258,268,269,270,271],"Implementation science","Social isolation","Physical activity","Mobility","Loneliness","Joint replacement","Feasibility","Acceptability","Fidelity","2026-03-10",{"date":274,"type":34},"2026-03-12",{"date":276,"type":34},"2025-07-14",{"date":278,"type":22},"2028-03",{"name":280,"class":41},"University of British Columbia",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":288,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":42},"100626741","wound-closure-materials-and-techniques-in-hip-and-knee-arthroplasty-100626741","NCT07439575","Wound Closure Materials and Techniques in Hip and Knee Arthroplasty","Evaluation of Different Suture Materials and Closure Techniques in Lower Extremity Arthroplasty: Effects on Wound Healing, Functional Outcomes, and Complications","Inclusion Criteria:\n\n* Age ≥ 30 years\n* Patients undergoing primary total hip arthroplasty or total knee arthroplasty\n* Patients undergoing aseptic revision total hip or knee arthroplasty\n* Surgery performed by the same surgical team\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 30 years\n* Patients receiving immunosuppressive therapy\n* Patients with complicated diabetes mellitus\n* Chronic venous insufficiency\n* Peripheral arterial disease\n* Arthroplasty performed due to malignancy\n* Active or previous surgical site infection","30 Years",{"count":290,"type":22},90,[25],"This prospective randomized clinical study aims to evaluate the effects of different suture materials and wound closure techniques on wound healing, functional outcomes, and postoperative complications in patients undergoing total hip and knee arthroplasty.\n\nA total of at least 90 adult patients undergoing primary or aseptic revision lower extremity arthroplasty will be randomized into two groups according to the wound closure material and technique used. All surgeries will be performed by the same surgical team following standardized operative protocols.\n\nPrimary outcomes include wound-related complications such as prolonged wound drainage, wound dehiscence, surgical site infection, and local inflammatory findings within 90 days postoperatively. Secondary outcomes include operative time, bleeding amount, cosmetic outcomes, and functional scores.\n\nThe results of this study are expected to help determine the most effective and safe wound closure method in lower extremity arthroplasty.",[170,28],[295,296,297,298,299,300,301],"Total Knee Arthroplasty","Total Hip Arthroplasty","Wound Closure","Barbed Suture","Surgical Site Infection","Wound Healing","Arthroplasty","2026-02-26",{"date":304,"type":34},"2026-03-02",{"date":306,"type":34},"2025-11-01",{"date":308,"type":22},"2026-08",{"name":310,"class":311},"Bahattin Kemah","OTHER_GOV",{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":17,"minAge":320,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":23,"phases":324,"briefSummary":325,"conditions":326,"keywords":332,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":42},"100564678","dexa-bone-density-analysis-of-the-corehip-prosthesis-system-100564678","NCT06632301","DEXA Bone Density Analysis of the CoreHip® Prosthesis System","DEXA Bone Density Analysis to Analyze the Loading Concept of the CoreHip® Prosthesis","CODEX","Inclusion Criteria:\n\n* Unilateral hip osteoarthritis\n* Indication for CoreHip Standard hip stem according to preoperative planning\n* Written Informed Consent\n* Age 35-85 years\n* According to the assessment of the study doctor, the patient is therapy compliant and able to attend the follow-up visits\n\nExclusion Criteria:\n\n* Femoral neck fractures\n* Pregnancy\n* BMI \\> 35\n* History of femoral fracture or previous surgery on the same hip\n* Metabolic bone disease, use of steroids or other drugs affecting bone metabolism\n* Intraoperative bone cracks\n* Severe osteoarthritis of the contralateral hip\n* THA of the contralateral side or other event leading to restricted weight bearing during the study period","35 Years","85 Years",{"count":323,"type":22},40,[25],"The goal of this interventional post-market follow-up study is to evaluate radiological changes in the diaphyseal bone density (Gruen Zones 3 and 4) within 24 months postoperative in patients treated with CoreHip® primary cementless stem. The DEXA bone density analysis is used.",[327,328,28,329,330,331],"Primary Osteoarthritis","Cartilage Degeneration","Inflammatory Arthritis","Osteonecrosis of Femoral Head","Traumatic Disorder",[296,333],"DEXA Bone Density Analysis","2026-02-24",{"date":336,"type":34},"2026-02-27",{"date":338,"type":22},"2026-06",{"date":340,"type":22},"2028-09",{"name":342,"class":156},"Aesculap AG",{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":17,"minAge":135,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":23,"phases":354,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":42},"100497728","phase-4-helping-osteoarthritis-patients-to-walk-with-nsaid-100497728","NCT05761015","Helping Osteoarthritis Patients to Walk With NSAID","A Rehabilitation Walking Program With the Help of a Transient Intake of Nonsteroidal Anti-inflammatory Drug for Patients With Painful Hip\u002FKnee Osteoarthritis - A Pilot Cohort Study With Objectives of Short Walks in the Real Life.","PERIPATEI","Inclusion Criteria:\n\n* Uni- or bilateral hip or knee idiopathic osteoarthrosis (ACR criteria, Kellgren-Lawrence grade 2 or more on recent X-ray), responsible for pain since 3 at least months, and pain at walking which intensity is at least 4\u002F10 on a numerical rating scale.\n* Less than 3 relevant walks (at least 20 minutes or 1000 km) a week.\n* Ability to understand and to follow the protocol, and to answer the questionnaires\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Legal protection\n* Body weight \\\u003C 40 kg or underweight\n* Body weight \\>120 kg or obesity\n* Unability to walk, or unability to walk without support devices (sticks, crutches, orthoses and knee pads are allowed)\n* Secondary osteoarthrosis (rheumatism, septic arthritis, recent osteonecrosis, hemochromatosis, gout, acromegalia…).\n* Concomitant general bone disease (Paget, Reiter…).\n* Concomitant and relevant painful disease else than due to osteoarthrosis (e.g. neuropathic pain, fibromyalgia…)\n* Previous recent intervention (e.g. surgery, arthroscopy, joint infiltration) expected to relief osteoarthrosis pain throughout the study period.\n* Planned intervention similar to those abovementioned, during the study period.\n* Recent initiation of any new analgesic treatment (including systemic steroids).\n* Planned initiation of any program expected to relief osteoarthrosis pain during the study period, such as physiotherapy, cognitive behavioral therapy…).\n* Planned major surgery during the study period.\n* Current cancer disease.\n* Immunosuppression.\n* Autoimmune disease.\n* Concomitant topical or systemic NSAID treatment.\n* Chronic strong opioid intake.\n* Concomitant insulin therapy.\n* Any absolute or relevant contraindication to NSAIDs or acetaminophen, according to the French drug agency","70 Years",{"count":353,"type":22},55,[355],"PHASE4","There is a lack of effective analgesic treatments to help walking patients with painful hip\u002Fknee osteoarthritis. Our team therefore imagined a new strategy lying on a multimodal rehabilitation walking program with the help of a transient intake of nonsteroidal anti-inflammatory drug (NSAID). NSAIDs are indeed known to act specifically on pain at movement, but their continuous intake would induce unacceptable side effects. To optimize the benefit\u002Frisk balance, the molecule to be chosen must fit to the patient's profile, and its intake should cover only the period of interest, i.e. planned walks. Our multimodal rehabilitation program will also include physical techniques such as appropriate footwear, a patient's education aiming at reducing fear\u002Favoidance and spotting side effects of NSAIDs, and a prescription frame to avoid any overdosing.\n\nThis clinical study is a single-center, non-randomized, open label, one-arm trial, using drugs prescribed according to their label (i.e. osteoarthritis pain), pending a reinforced monitoring of side effects.\n\nThe primary endpoint is to evaluate efficacy and tolerance of a tailored and transient administration of NSAID within a rehabilitation walking program in patients with painful hip\u002Fknee osteoarthritis.\n\nSecondary endpoints are to evaluate the adherence to the program and the factors influencing adherence; to identify the less well tolerated conditions of treatment (one condition being one molecule for one patient profile); to identify the factors of success among a set of baseline demographic, morphometric and psychometric variables; and to study the role of central sensitization (assessed by temporal summation) on the efficacy of treatment.",[170,28,358],"Chronic Pain",[170,28,360,361,362,363,364,365],"pain at movement","nonsteroidal anti-inflammatory drug","acetaminophen","paracetamol","personalized medicine","pharmacovigilance",{"date":336,"type":34},{"date":368,"type":34},"2023-12-14",{"date":370,"type":22},"2028-04",{"name":372,"class":41},"University Hospital, Clermont-Ferrand",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":17,"minAge":379,"maxAge":380,"enrollmentInfo":381,"targetDuration":4,"studyType":23,"phases":383,"briefSummary":384,"conditions":385,"keywords":391,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":42},"100579345","early-feasibility-study-of-cartilage-defect-repair-100579345","NCT06823089","Early Feasibility Study of Cartilage Defect Repair","Inclusion Criteria:\n\n1. At least 14 years of age to no older than 64 years of age Subjects 14-21 years of age must have radiographic evidence of epiphyseal closure in the hip joint\n2. BMI \\\u003C 35\n3. Failed at least 6 weeks of conservative treatment (e.g., anti-inflammatory pain medications, physical therapy, injections)\n4. Duration of symptoms consistent with intra-articular disease (i.e., groin, lateral and\u002For posterior hip pain) that have persisted for at least 3 months)\n5. Loss of articular cartilage integrity (\\~1 - 6 cm\\^2 in area) on the femoral head (confirmed by MRI), without an opposing lesion, that can be treated with a single ReNew Hip Implant\n6. Radiographic assessment with joint space width \\> 2 mm (verified by x-ray)\n7. Meets an acceptable preoperative medical clearance and is free of conditions that would pose excessive operative risk, in the opinion of the investigator\n8. Given consent to participate in the study\n9. Able to understand the purpose of the study, his\u002Fher role, and is available for follow-up for the duration of the study:\n\n   1. Subject has signed an IRB (Institutional Review Board) approved Informed Consent Form agreeing to participate in the extension study after the nature, scope, and possible consequences of the study have been explained in an understandable form\n   2. Subject is able to fully understand the purpose of the study, his\u002Fher role as a participant in the study, and plans to be available through five years post-operative follow-up\n\nExclusion Criteria:\n\n1. Current users of nicotine in any form (e.g., cigarettes, e- cigarettes\u002Fvaping, chewing tobacco, nicotine patches, gum, lozenges), or individuals who have discontinued nicotine use less than 30 days prior to screening.\n2. Type 1 or Type 2 Diabetes\n3. Systemic steroid use in the 3 months prior to screening\n4. Coxa plana, coxa magna, or proximal femoral focal deficiency on the femoral head that would result in implant mismatch of the femoral head contour\n5. Any acute or chronic condition that would limit the ability of the patient to participate in the study (e.g., COPD, congestive heart failure),\n6. Bleeding disorders\n7. Current cancer (with the exception of non-melanoma skin cancer)\n8. Pregnancy or planning to become pregnant during the study period\n9. Active infection or sepsis\n10. History of local hip infection\n11. Known metastatic or neoplastic disease\n12. Conditions that may interfere with implant survival or outcomes (e.g., severe dysplasia)\n13. Life expectancy less than 2 years\n14. Intra-articular therapy within 3 months of enrollment\n15. Inadequate bone stock (as determined by SCORE or MORES assessment) to support the device\n16. Femoral head is:\n\n    1. outside of the 46 - 56 mm range in either anteroposterior diameter or lateral diameters or\n    2. an aspherical head deformity that results in contour mismatch of 16a\n17. Moderate to severe renal insufficiency\n18. Emotional or neurological condition that would preempt ability or willingness to participate in the study\n19. Above the knee amputation of the contralateral or ipsilateral leg\n20. Known allergies to the components of the device (polycaprolactone)\n21. Is a prisoner","14 Years","64 Years",{"count":382,"type":22},15,[25],"Any patient aged 14 or older up to 64 years of age with hip disease, resulting in loss of articular cartilage integrity on the femoral head (e.g., femoroacetabular impingement or other structural deformity), has failed conservative care, and is a candidate for surgical intervention to treat.",[28,386,387,388,389,390],"Femoroacetabular Impingement","Osteonecrosis","Legg-Calvé-Perthes Disease","Osteochondral Lesion","Hip Dysplasia",[392,393,394,395,396,397,398,399,400,401,402,403,404],"articular cartilage","hip resurfacing","residual Perthes disease","post-Perthes deformity","femoral head deformity","secondary hip osteoarthritis","hip preservation surgery","adolescent hip deformity","adult hip deformity","avascular necrosis of femoral head","early-stage avascular necrosis","Perthes sequelae","traumatic femoral head lesion","2026-02-12",{"date":407,"type":34},"2026-02-17",{"date":409,"type":34},"2025-11-06",{"date":411,"type":22},"2031-10",{"name":413,"class":41},"Cytex Therapeutics, Inc.",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":423,"briefSummary":424,"conditions":425,"keywords":427,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":42},"100340381","outcomes-of-low-impact-exercise-program-for-people-with-ankle-knee-andor-hip-pain-100340381","NCT03711773","Outcomes of Low-Impact Exercise Program for People With Ankle, Knee, and\u002For Hip Pain","Outcomes of Low-Impact Group Exercise Program for People With Ankle, Knee, and\u002For Hip Pain","Inclusion Criteria:\n\n* 18 and over\n* Ability to attend classes 3x weekly for 6 months with at least a 66% attendance rate\n* Ability to concurrently attend standard of care dietitian and behavioral health classes for 6 months\n* Joint pain (knee, ankle, hip)\n\nExclusion Criteria:\n\n* Pregnant\n* Prisoners",{"count":422,"type":22},10000,[25],"The primary objective of this study is to study how low-impact group exercise classes affect pain scores in patients with knee, hip, and ankle pain when paired with concurrent standard of care dietitian and behavioral health consults.",[253,170,28,426],"Osteoarthritis Ankle",[428,176,429,430,431],"joint pain","hip pain","knee pain","ankle pain",{"date":433,"type":34},"2026-02-02",{"date":435,"type":34},"2018-11-01",{"date":437,"type":22},"2030-01-01",{"name":439,"class":41},"University of Missouri-Columbia",{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":23,"phases":448,"briefSummary":449,"conditions":450,"keywords":451,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":71},"100503013","6-month-efficacy-and-safety-of-synolis-va-80160-in-hip-osteoarthritis-100503013","NCT05829733","6-month Efficacy and Safety of Synolis VA 80\u002F160 in Hip Osteoarthritis","6-month Evaluation of the Efficacy and Safety of Synolis VA 80\u002F160 in the Treatment of Symptomatic Hip Osteoarthritis","Inclusion Criteria:\n\n* Patient over 18 years of age,\n* Patient with osteoarthritis of the hip. The diagnosis is based on the following criteria:\n* Treated hip pain: Oxford score ≥ 21\u002F60,\n* Kellgren-Lawrence positive X-ray stage: II - III (inclusion radiograph dated no more than 6 months before the inclusion visit),\n* Symptoms related to osteoarthritis of the hip for at least 2 months,\n* Failure of treatments (i.e., inadequate or ineffective response to analgesics and\u002For NSAIDs or intolerance to NSAIDs or low-grade opioids (leaving an OXFORD score ≥ 21\u002F60),\n* Informed consent form signed by the patient,\n* The patient has never had a visco supplement injection or corticosteroid injection in the hip to be treated (or more than 6 months old).\n\nExclusion Criteria:\n\n* Pregnancy,\n* Participation in another clinical trial,\n* Skin lesion near the injection site,\n* Recent or old infection of the affected joint,\n* Patient with a programmed arthroplasty,\n* Patient with a pathology that makes decision-making impossible,\n* The patient must not have undergone non-prosthetic hip-conserving surgery such as osteotomy or arthroscopy less than 12 months old.",{"count":82,"type":22},[25],"Multicenter, independent study of Synolis VA 80\u002F160 over a period of 6 months",[28],[253,452,453],"Hip osteoarthritis","Hyaluronic acid","2025-12-05",{"date":456,"type":34},"2025-12-12",{"date":458,"type":34},"2024-05-27",{"date":460,"type":22},"2027-04",{"name":462,"class":156},"Aptissen SA",{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":471,"sex":17,"minAge":18,"maxAge":472,"enrollmentInfo":473,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":475,"conditions":476,"keywords":478,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":239},"100460660","complex-molecular-etiology-and-cellular-landscape-of-hip-osteoarthritis-100460660","NCT05278520","Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis","Studies on the Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis","OASEQ","Inclusion Criteria for the main (OA) study:\n\nCases: Adult patients with osteoarthritis in the hip joint and who are going through an elective total hip arthroplasty.\n\nControls: Non-arthritis adult patients who are going through a trauma-based emergency total hip arthroplasty.\n\n\\----\n\nInclusion Criteria for the Rheumatoid sub-study:\n\nAdult patients with rheumatoid arthritis in the hip joint and who are going through an elective total hip arthroplasty.\n\n\\----\n\nExclusion Criteria:\n\n* The body mass index must be below 35\n* Age \\\u003C 18 or \\> 74\n* The OA patients may not have diabetes, rheumatoid arthritis (RA), or metabolic syndrome.\n\nFor the Rheumatoid sub-study, the exclusion criteria are the same as above except for the RA.",true,"74 Years",{"count":474,"type":22},110,"The purpose of this study is to cast light on the highly complex etiology and cellular landscape of hip osteoarthritis by utilising single-cell and spatial omics.",[28,477],"Rheumatoid Arthritis",[479,480,253,481,482],"Single-cell RNA sequencing","Spatial transcriptomics","Rheumatoid arthritis","Spatial proteomics","2025-08-18",{"date":485,"type":34},"2025-08-24",{"date":487,"type":34},"2023-01-11",{"date":489,"type":22},"2028-12",{"name":491,"class":41},"University of Turku",{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":17,"minAge":500,"maxAge":52,"enrollmentInfo":501,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":503,"conditions":504,"keywords":510,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":42},"100493094","perfusion-mri-targeted-joint-embolization-for-chronic-musculoskeletal-pain-of-the-shoulder-hip-and-knee-100493094","NCT05700682","Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee","Perfusion MRI-targeted Joint Embolization to Diagnose and Treat Neovascularity Associated With Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee: A Prospective Cohort Study","MRI","Inclusion Criteria (Both Arms):\n\n1. Participants must be Veterans who receive care in the VA system.\n2. Participants must have a history of chronic pain of the shoulder, hip or knee for at least 1 year.\n3. Participants must have mild to moderate degenerative changes of the painful joint as depicted on prior imaging (X-ray, CT or MRI).\n4. Participants must have undergone at least one failed primary treatment for their chronic pain (e.g. physical therapy, NSAIDs, steroid injection).\n5. Participants must have an MRI of their painful joint (shoulder, hip or knee) ordered by a clinical provider.\n\nInclusion Criteria (Therapeutic Arm):\n\n1. Participants must have enrolled in the Diagnostic Arm of the study and must have undergone perfusion MR imaging of their painful joint.\n2. Participants must have evidence of peri-articular hypervascularity on their perfusion MR exams. This will be determined by the study PIs.\n\nExclusion Criteria (Diagnostic Arm):\n\n1. Acute injury in the last 12 weeks.\n2. Age under 25.\n3. Severe degenerative changes of painful joint (shoulder, hip or knee).\n4. History of arthroplasty or metallic implant within the painful joint.\n5. Severe gadolinium contrast allergy.\n6. Severe renal disease or ongoing dialysis.\n7. History of malignancy with life expectancy of less than one year, or malignancy with known bone metastasis.\n8. Current pregnancy.\n9. Formal diagnosis of cognitive impairment.\n\nExclusion Criteria (Therapeutic Arm):\n\n1. Severe iodinated contrast allergy.\n2. Severe coronary or peripheral arterial disease.\n3. Coagulopathy.\n4. Uncontrolled type 2 diabetes or diabetic neuropathy.\n5. History of seizures or other severe complication from conscious sedation.\n6. Prior upper or lower extremity arterial bypass.\n7. Ongoing participation in another interventional (therapeutic) trial for chronic joint pain.\n8. Lack of peri-articular hypervascularity on initial perfusion MRI.\n9. All exclusion criteria for the Diagnostic Arm.","25 Years",{"count":502,"type":22},120,"In this work the investigators will study the relationship between chronic musculoskeletal pain and abnormal blood flow (neovascularity) around the shoulder, hip and knee. Veterans with as history of chronic shoulder, hip or knee pain and mild\u002Fmoderate joint degenerative changes will be potential study subjects. Blood flow around joints will be evaluated using perfusion magnetic resonance imaging (MRI). Participants with demonstrably abnormal blood flow around their painful joint will be eligible for enrollment in a pilot study of joint embolization to treat their pain. Participants who choose to not undergo treatment will be re-assessed with MRI after one year to characterize the natural history of joint neovascularity and its relationship to pain.",[170,28,505,506,507,508,509],"Osteo Arthritis Shoulders","Synovitis of Knee","Synovitis\u002FTenosynovitis - Hip","Synovitis","Pain, Chronic",[511,512,513,514,515,516,517],"joint","embolization","neovascularity","pain","knee","hip","shoulder","2025-08-04",{"date":520,"type":34},"2025-08-07",{"date":522,"type":34},"2023-07-15",{"date":524,"type":22},"2026-08-01",{"name":526,"class":41},"Palo Alto Veterans Institute for Research",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":535,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":71},"100542436","direct-superior-approach-versus-posterolateral-approach-in-total-hip-arthroplasty-splash-100542436","NCT06342843","Direct Superior Approach Versus PosteroLateral Approach in Total Hip Arthroplasty (SPLAsH)","Direct Superior Approach Versus PosteroLateral Approach in Total Hip Arthroplasty: a Multicenter Double Blinded Randomized Controlled Trial","SPLAsH","Inclusion Criteria:\n\nSubject\n\n* Has symptomatic incapacitating coxarthrosis in whom total hip arthroplasty (THA) is indicated, diagnosed by both physical examination and pelvic\u002Fhip X-ray\n* Has signed informed consent\n* Is ageing 18 years or older at time of study entry\n* Is competent and able to participate in follow-up\n\nExclusion Criteria:\n\n* Previous ipsilateral hip surgery\n* BMI \\>35 kg\u002Fm2\n* Contralateral incapacitating coxarthrosis, diagnosed by both physical examination and pelvic\u002Fhip X-ray\n* Neurological conditions influencing walking pattern\n* Inability to walk without walking aid preoperatively\n* Rheumatoid arthritis (RA)\n* Severe hip dysplasia\n* Cognitive impairment\n* Malignancies or metastases involving the hip joint or the nearby soft tissues\n* Inability to speak and write Dutch language","99 Years",{"count":537,"type":22},211,[25],"This study will compare postoperative pain, health related quality of life (HRQoL), function, rehabilitation, urinary incontinence, muscle atrophy and component positioning in total hip arthroplasty (THA) using the posterolateral approach (PLA) or the direct superior approach (DSA). In addition, the CT images will be used to validate a new metal artefact reduction technique.",[28],"2025-07-30",{"date":543,"type":34},"2025-08-03",{"date":545,"type":34},"2024-03-26",{"date":547,"type":22},"2027-12-31",{"name":549,"class":41},"Isala",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":558,"targetDuration":4,"studyType":23,"phases":560,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":42},"100452263","phase-2-antibiotic-impregnated-bone-graft-to-reduce-infection-in-hip-replacement-100452263","NCT05169229","Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.","Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement. The ABOGRAFT Trial","ABOGRAFT","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Hip arthroplasty requiring bone graft\n3. Willing to provide informed consent.\n4. For women of childbearing potential; a negative pregnancy test prior to reoperation.\n\nExclusion Criteria:\n\n1. Ongoing prosthetic joint infection\n2. Known allergies and contraindications for the use of vancomycin or tobramycin\n3. Mental inability, reluctance, or language difficulties that according to investigator judgement, result in difficulty understanding the meaning of study participation\n4. Expected difficulties to complete 2-year follow-up\n5. Females of child bearing potential not using contraception\n6. Pregnant females\n7. Nursing females",{"count":559,"type":22},1100,[561,562],"PHASE2","PHASE3","Total hip replacement is the most successful treatment modern healthcare can offer patients to regain quality of life. Periprosthetic joint infection (PJI) is the most common and devastating complication after total hip replacement (THR). Between 0.5 to 2% of primary THR (first time hip replacement), and 8-10% of revision THR (replacement of a hip prosthesis) will become infected.1 The introduction of local antibiotics blended into bone cement has led to a reduction in postoperative infection in primary THR by half.2 Unfortunately, cement can't always be used in relevant quantities.\n\nThe number of primary and revision surgeries of the hip is projected to increase dramatically. Therefore, the need for a feasible infection prophylaxis that is applicable for complex primary and revision THR in addition to antibiotics loaded cement is urgent.\n\nImpacted morselized bone allograft is often used in (revision) THR to fill bone defects. Morselized allograft has been used as a carrier for local antibiotic treatment in multiple pilot studies and appears to be an attractive and effective treatment option, both for already infected joints and as a prophylactic measure in high-risk patients (e.g. THR revision surgeries). Nonetheless, a pivotal trial to support its use in THR is lacking. The aim of this pragmatic randomized controlled double blinded drug trial is to investigate whether antibiotic impregnated bone graft (AIBG) decreases the risk of infection after hip arthroplasty compared to controls treated with placebo impregnated bone graft. Patients scheduled for elective THR will be randomized to receive AIBG or a placebo impregnated bone graft. The primary outcome variable will be the number of re-operations due to infections and PJI diagnoses 2 years postoperative.",[565,28,566,567],"Arthroplasty, Replacement, Hip","Antibiotic Resistant Infection","Prosthetic Joint Infection","2025-07-17",{"date":570,"type":34},"2025-07-22",{"date":572,"type":34},"2022-04-01",{"date":574,"type":22},"2031-12",{"name":576,"class":41},"University Hospital, Linkoeping",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":587,"conditions":588,"keywords":589,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":42},"100522864","changes-in-postural-stability-following-tha-for-oa-100522864","NCT06088160","Changes in Postural Stability Following THA for OA","Changes in Postural Stability and Balance Confidence in People After Elective Unilateral Total Hip Arthroplasty for Osteoarthritis: A Prospective Cohort Study","CPS","Inclusion Criteria:\n\n* ≥ 60 years of age, scheduled to receive an elective unilateral THA (DA or DL approach) for OA\n* Ambulatory for a minimum of 10 meters with or without a mobility aid but without the assistance of another person\n* Able to read, write and speak English\n* Able to provide consent\n\nExclusion Criteria:\n\n* Bilateral THA\n* Underwent THA surgery for a diagnosis other than OA\n* Any condition that will prevent participants from completing the study such as having a significant neurological, cardiovascular, musculoskeletal condition as denoted by their physician.",{"count":586,"type":22},80,"Total hip arthroplasty (THA) is a common surgery that eases pain, restores functional movement, and improves the overall quality of life in people with severe hip osteoarthritis (OA). Unfortunately, problems with postural stability, commonly known as balance, are still noticed in people even years after the surgery. These postural stability problems typically result in falls. The aim of the proposed study is to investigate how THA surgery affects a person's overall quality of life, both physically and psychologically, in terms of postural stability and balance confidence (self-efficacy) within the first three months after THA for osteoarthritis. This prospective cohort study will focus on people over 60 years old.",[28],[590,591,592,253,593],"Postural stability","Total hip arthroplasty","Balance confidence","Fall","2025-07-16",{"date":596,"type":34},"2025-07-20",{"date":598,"type":34},"2023-12-27",{"date":600,"type":22},"2025-11",{"name":602,"class":41},"Western University, Canada",{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":471,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":23,"phases":612,"briefSummary":613,"conditions":614,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":629},"100420387","g7-acetabular-system-with-vivacit-e-or-longevity-liner-pmcf-study-100420387","NCT04754087","G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study","Global, Multicenter, and Prospective Post-Market Clinical Follow-Up Study of the G7 Acetabular System With Vivacit-E and Longevity Highly Crosslinked Polyethylene (HXLPE) Liners & Instrumentation","Inclusion Criteria:\n\n* Patient must be a legal adult who has reached full skeletal maturity.\n* Patient must be treated for one of the following indications:\n* Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis\n* Rheumatoid arthritis\n* Correction of functional deformity\n* Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques\n* Revision procedures where other treatment or devices have failed\n* Patient must be able and willing to complete the protocol required follow-up visits.\n* Patient must be able and willing to sign the Institutional Review Board or Ethics Committee (IRB\u002FEC) approved informed consent.\n\nExclusion Criteria:\n\n* Patient presents with osteoporosis, which in the opinion of the Principal Investigator, may limit the subject's ability to support total hip arthroplasty using the study device.\n* Patient has a metabolic disorder that may impair bone formation.\n* Patient has osteomalacia.\n* Patient has distant foci of infections which may spread to the implant site or patient with infection, sepsis or osteomyelitis.\n* Patient has rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram.\n* Patient has a vascular insufficiency, muscular atrophy, or neuromuscular disease\n* Patient is a prisoner.\n* Patient is a current alcohol or drug abuser.\n* Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions.\n* Patient is pregnant.",{"count":611,"type":22},300,[25],"The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Acetabular Shells when used with the Vivacit-E and Longevity HXLPE liners and instrumentation in primary and revision total hip arthroplasty.",[296,615,143,616,28,617,618,619],"Degenerative Joint Disease of Hip","Rheumatoid Arthritis of Hip","Osteoarthritis of Hip","Fractures, Hip","Fracture of Hip","2025-06-13",{"date":622,"type":34},"2025-06-18",{"date":624,"type":34},"2021-07-07",{"date":626,"type":22},"2033-12-31",{"name":628,"class":156},"Zimmer Biomet",11,{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":17,"minAge":637,"maxAge":638,"enrollmentInfo":639,"targetDuration":4,"studyType":23,"phases":641,"briefSummary":642,"conditions":643,"keywords":644,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":42},"100484159","digitalization-of-osteoarthritis-care-100484159","NCT05584410","Digitalization of Osteoarthritis Care","Digitalization of the Care for Patients With Hip and Knee Osteoarthritis","Inclusion Criteria:\n\nThe participant:\n\n* has given their written consent to participate in the study\n* has been referred to the orthopaedic clinic at Sahlgrenska University Hospital \u002FMölndal for primary hip- and or knee osteoarthritis\n* has a positive attitude in using digital tools\n* has access to a smart phone \u002F tablet\n* has been assessed not to be in need of hip or knee surgery trough triage based on a patient reported outcome (the Osteoarthritis Guidelines Instrument)\n\nExclusion Criteria:\n\nPatients:\n\n* with secondary osteoarthritis (due to osteonecrosis)\n* referred to a specific orthopaedic surgeon\n* with impaired mental ability, reluctance or language difficulties that make it difficult to understand the meaning of participating in the study\n* who undergo treatment, have disability or illness that according to the research group can affect the treatment or the study result","20 Years","90 Years",{"count":640,"type":22},315,[25],"The overall aim of this study is to compare three different care models for patients with hip- and knee osteoarthritis. The primary aim is to evaluate whether an app-based care model is more beneficial for improving function in daily life than a web-based care model and standard care for patients with hip and \u002F or knee osteoarthritis",[170,28],[645,176,646],"physiotherapy","digital care","2025-05-26",{"date":649,"type":34},"2025-05-31",{"date":651,"type":34},"2022-12-05",{"date":653,"type":22},"2028-12-31",{"name":655,"class":311},"Vastra Gotaland Region",{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":664,"targetDuration":4,"studyType":23,"phases":666,"briefSummary":667,"conditions":668,"keywords":669,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":42},"100366285","migration-in-total-hip-arthroplasty-with-a-cemented-bimobile-cup-better-stability-with-more-cement-100366285","NCT04049279","Migration in Total Hip Arthroplasty with a Cemented BiMobile Cup: Better Stability with More Cement?","Migration in Total Hip Arthroplasty with a Cemented BiMobile Cup: Better Stability with More Cement? (Be-Mobile)","Be-Mobile","Inclusion Criteria:\n\n* Patient requiring an elective primary cemented THA.\n* Male patient ≥70 years old and female patient ≥65 years old.\n* Ability and willingness to follow instructions and to return for follow-up evaluations.\n* The patient is able to understand the meaning of the study and is willing to sign informed consent.\n* Understanding the Dutch language.\n\nExclusion Criteria:\n\n* The patient is morbidly obese, defined as Body Mass Index (BMI) of ≥ 40.\n* The patient is expected to need lower limb joint replacement for another joint within one year.\n* The patient has a systemic or metabolic disorder leading to progressive bone deterioration.\n* The patient has a deformity or disease located in other joints than the hip that needs surgery and that is limiting their ability to walk.\n* The patient has an active or suspected latent infection in or around the hip joint.\n* The patient's bone stock is compromised by a disease or infection which cannot provide adequate support and\u002For fixation to the prosthesis.\n* The patient is unable or unwilling to sign informed consent for this study.\n* The patient is deemed unsuitable for participation in the study based on the investigator's judgment.",{"count":665,"type":22},75,[25],"Objective: The main objective of this study is to compare the (early) migration of the cemented BiMobile cup at two year post-surgery between two different cup sizes after standard optimal reaming, and consequently adjusting the cement mantle into circa 2 or 4 mm, in patients with a primary cemented total hip arthroplasty (THA). Additionally, the results of the BiMobile cup will be compared to the Avantage cup, which is placed with a standard cup size, resulting in a cement mantle of approximately 2 mm.\n\nStudy design: A prospective single centre blinded randomised controlled trial.\n\nStudy population: All patients who meet the criteria to undergo a cemented THA.",[296,28],[670,671,672,673],"primary total hip arthroplasty","RSA","cement","Dual mobility cup","2025-02-25",{"date":676,"type":34},"2025-02-28",{"date":678,"type":34},"2019-01-01",{"date":680,"type":22},"2029-05-01",{"name":682,"class":41},"JointResearch",{"id":684,"slug":685,"hasResults":12,"nctId":686,"briefTitle":687,"officialTitle":688,"acronym":689,"eligibilityCriteria":690,"healthyVolunteers":12,"sex":17,"minAge":351,"maxAge":4,"enrollmentInfo":691,"targetDuration":4,"studyType":23,"phases":692,"briefSummary":693,"conditions":694,"keywords":695,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":698,"startDateStruct":699,"completionDateStruct":700,"leadSponsor":702,"locationsCount":42},"100364944","dual-mobility-cups-compared-to-unipolar-cups-on-dislocation-and-cost-effectiveness-after-primary-total-hip-arthroplasty-100364944","NCT04031820","Dual-mobility Cups Compared to Unipolar Cups on Dislocation and Cost-effectiveness After Primary Total Hip Arthroplasty.","Effectiveness of Dual-mobility Cups for Preventing Dislocation After Primary Total Hip Arthroplasty by a Posterolateral Approach and Their Cost-effectiveness Compared to Unipolar Cups in Elderly Patients.","REDEP","Inclusion Criteria:\n\n* Patients who are eligible for elective primary THA with a cemented cup, with a 32mm or 36 mm liner, for any indication.\n* THA using posterolateral surgical approach.\n* Patients ≥ 70 years old\n* Adequate comprehension of written and spoken Dutch\n\nExclusion Criteria\n\n* Patients unable to complete PROMs\n* Patients with dementia, epilepsy\\*, spasticity\\*, mental retardation or alcoholism. (If dementia or mental retardation is not already mentioned in the medical chart, this can be determined by doctors opinion.)\n* Patients not eligible for either a unipolar or a DM cup\n\n  * These patients will be asked to participate in the non-randomized dual mobility observational cohort.",{"count":559,"type":22},[25],"Objective: The primary objective is to investigate whether there is a difference in the number of hip dislocations following primary total hip arthroplasty (THA), using the posterolateral approach, with a DM cup compared to a unipolar cup in elderly patients 1 year after surgery.\n\nStudy design: Prospective multi-center nation wide, single blinded RCT nested in the LROI.\n\nStudy population: Patients ≥ 70 years old, undergoing an elective primary cemented THA.",[296,28],[696,697],"Primary total hip arthroplasty","Dual Mobility cup",{"date":676,"type":34},{"date":678,"type":34},{"date":701,"type":22},"2027-05-01",{"name":682,"class":41},{"id":704,"slug":705,"hasResults":12,"nctId":706,"briefTitle":707,"officialTitle":708,"acronym":709,"eligibilityCriteria":710,"healthyVolunteers":12,"sex":17,"minAge":711,"maxAge":52,"enrollmentInfo":712,"targetDuration":4,"studyType":23,"phases":714,"briefSummary":715,"conditions":716,"keywords":717,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":721,"lastUpdatePostDateStruct":722,"startDateStruct":724,"completionDateStruct":726,"leadSponsor":728,"locationsCount":42},"100560517","phase-3-the-effect-of-colchicine-on-the-incidence-of-knee-or-hip-replacements-100560517","NCT06578182","The Effect of ColcHicine on the Incidence of Knee or Hip Replacements","The Effect of ColcHicine on the Incidence of Knee or Hip Replacements: a Randomized, Double-blind, Multicentre Study in Symptomatic Knee or Hip Osteoarthritis","ECHO","Inclusion Criteria:\n\n* clinical diagnosis of knee or hip OA\n* 45 ≤ age ≤ 80 (upper age limit is similar to that in the LoDoCo2 trial and takes in consideration the lower number of joint replacements in people older than 80 years)\n* documented radiographic changes typical for advanced knee\u002Fhip OA (Kellgren \\& Lawrence score ≥ 2), or at least 2-year history of complaints due to OA in the hip and\u002For knee\n\nExclusion Criteria:\n\n* On a waiting list for primary joint replacement surgery of the hip or knee, irrespective of cause\n* Any absolute contraindication for knee or hip replacement in the future\n* More than one previous hip or knee replacements\n* Other known medical disease that may affect joints\n* Known generalized pain syndromes such as fibromyalgia\n* Renal impairment as evidenced by serum creatinine \\>150µmol\u002Fl or estimated glomerular filtration rate (eGFR) \\\u003C50mL\u002Fmin\u002F1.73m2\n* Liver function impairment as evidenced by serum alanine transferase (ALAT) \\> 3 ULN (upper limit of normal)\n* Blood dyscrasia\n* High frailty (clinical frailty scale ≥ 7) or predicted life expectancy \\\u003C 5 years\n* Peripheral neuritis, myositis or marked myo-sensitivity to statins\n* Current use of colchicine for another indication\n* Intolerance to colchicine\n* use of macrolide antibiotics (i.e. clarithromycin, erythromycin, azithromycin), antimycotics (i.e. ketoconazole, itraconazole and voriconazole), protease inhibitors \\& anti-retroviral drugs (i.e. ritonavir, lopinavir, tipranavir, atazanavir, darunavir, indinavir, saquinavir, and cobicistat), anti-arrhythmic drugs (i.e. verapamil, diltiazem), or immunosuppressant (i.e. cyclosporine)\n* Current enrollment in another trial\n* Incapacitated patients\n* Pregnant or breastfeeding female\n* Fertile female participants not taking sufficient anti-conception\n* Male participants unwilling to use effective contraception during the study to prevent pregnancy","45 Years",{"count":713,"type":22},1410,[562],"The goal of this clinical trial is to evaluate the effect of treatment with colchicine 0.5mg once daily as compared to placebo in patients with knee or hip osteoarthritis on the incidence of first occurrence of knee or hip replacement. The main question it aims to answer is:\n\nDoes colchicine lower the number of knee or hip replacements in participants with osteoarthritis?\n\nResearchers will compare colchicine to a placebo (a look-alike substance that contains no drug) to see if colchicine works to treat osteoarthritis.\n\nParticipants will:\n\n* take colchicine every day for 3 tot 4.5 years\n* visit the clinic every year for check-up and tests such as blood samples and x-rays\n* fill in questionnaires every 3 months",[170,28],[718,719,720],"Colchicine","Knee replacement","Hip replacement","2025-02-18",{"date":723,"type":34},"2025-02-20",{"date":725,"type":34},"2025-01-01",{"date":727,"type":22},"2029-03-31",{"name":729,"class":41},"Sint Maartenskliniek"]